Lexicon Pharmaceuticals (LXRX) EPS (Weighted Average and Diluted) (2017 - 2026)
Lexicon Pharmaceuticals (LXRX) reported EPS (Weighted Average and Diluted) of -$0.0 for Q1 2026, up 96.44% year-over-year from -$0.0 in Q1 2025, and up 93.78% quarter-over-quarter from -$0.04 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) EPS (Weighted Average and Diluted) (2017 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.0 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.0, up 96.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.07 (up 86.27% YoY), and the FY2025 annual result was -$0.14, up 77.78% from the prior year.
- EPS (Weighted Average and Diluted) advanced to -$0.0 in Q1 2026 per LXRX's latest filing, from -$0.04 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.01 in Q2 2025 and troughed at -$0.22 in Q2 2023.
- A 5-year average of -$0.13 and a median of -$0.17 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) slumped 61.54% in 2023, then soared 105.88% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.17 in 2022, then decreased by 17.65% to -$0.2 in 2023, then soared by 55.0% to -$0.09 in 2024, then jumped by 55.56% to -$0.04 in 2025, then soared by 93.78% to -$0.0 in 2026.
- Business Quant data shows LXRX's EPS (Weighted Average and Diluted) at -$0.0 in Q1 2026, -$0.04 in Q4 2025, and -$0.04 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00 |
| Dec 31, 2025 | -0.04 |
| Sep 30, 2025 | -0.04 |
| Jun 30, 2025 | 0.01 |
| Mar 31, 2025 | -0.07 |
| Dec 31, 2024 | -0.09 |
| Sep 30, 2024 | -0.18 |
| Jun 30, 2024 | -0.17 |
| Mar 31, 2024 | -0.20 |
| Dec 31, 2023 | -0.20 |
| Sep 30, 2023 | -0.21 |
| Jun 30, 2023 | -0.22 |
| Mar 31, 2023 | -0.17 |
| Dec 31, 2022 | -0.17 |
| Sep 30, 2022 | -0.13 |
| Dec 31, 2021 | -0.17 |
| Sep 30, 2021 | -0.16 |
| Dec 31, 2020 | -0.03 |
| Sep 30, 2020 | 0.71 |
| Dec 31, 2019 | -0.48 |